Year: 2010
Type: article
Abstract: Atrophy measured on structural magnetic resonance imaging (sMRI) is a powerful biomarker of the stage and intensity of the neurodegenerative aspect of Alzheimer's disease (AD) pathology. In this review, we will discuss the role of sMRI as an AD biomarker by summarizing (a) the most commonly used methods to extract information from sMRI images, (b) the different roles in which sMRI can be used as an AD biomarker, and (c) comparisons of sMRI with other major AD biomarkers.
Source: Alzheimer s Research & Therapy
DOI: 10.1186/alzrt47
Authors: Prashanthi Vemuri, Clifford R Jack
Institution: Mayo Clinic
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,290
Awards: G3146424788, Evaluating and Extending Our Hypothetical Model of Alzheimer's Biomarkers, Alzheimer's Disease Neuroimaging Initiative, G5884129571, G6206414941, Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkers, Mayo Alzheimer's Disease Research Center
OpenAlex ID: W1987909254
